Please wait a minute...
Journal of Neurorestoratology  2021, Vol. 9 Issue (2): 83-93    doi: 10.26599/JNR.2021.9040012
Review Article     
Research progress on the therapeutic effect of olfactory ensheathing cell transplantation on ischemic stroke
Jin Wang1,Jianhua Zhao1,(✉)(),Shaomin Li2
1Henan Joint International Research Laboratory of Neurorestoratology for Senile Dementia, Henan Key Laboratory of Neurorestoratology, Department of Neurology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, Henan, China
2Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston 02115, Massachusetts, United States
Download: PDF (1268 KB)      HTML
Export: BibTeX | EndNote (RIS)      


Olfactory ensheathing cells (OECs) are a special type of glial cell in the olfactory system, which exhibit neuroprotective, immunomodulatory, and angiogenic effects. Although many studies have focused on the reversal of demyelination and axonal degeneration (during spinal cord injury) by OECs, few reports have focused on the ability of OECs to repair ischemic nerve injury. This article reviews the protective effects of OEC transplantation in ischemic stroke and provides a theoretical basis and new strategy for OEC transplantation in the treatment of ischemic stroke.

Key wordsischemic stroke      olfactory ensheathing cells      cell therapy      cerebrovascular disease     
Received: 15 May 2021      Published: 19 October 2021
Corresponding Authors: Jianhua Zhao     E-mail:
Cite this article:

Jin Wang,Jianhua Zhao,Shaomin Li. Research progress on the therapeutic effect of olfactory ensheathing cell transplantation on ischemic stroke. Journal of Neurorestoratology, 2021, 9: 83-93.

URL:     OR

Fig. 1The injury pathways secondary to ischemic stroke. Reproduced from Ref. [29].
ReferenceSubjectOECs sourceDose (cells)Transplant timingRoute
[64]PatientsOECs in an aborted fetus5.0 × 10612 months or more after ischemiaIN
[22]RatOECs in newborn SD rats3.0 × 10514 days after ischemia-reperfusionIC
[65]RatHuman nasal polyps OECs1.0 × 1051 day after ischemia (no reperfusion)IC
[66]RatTransgenic rats OECs5.0 × 105Ischemia-reperfusionIC
[67]PatientsFetal OECs1.0 × 105Sequelae of stroke or chronic phaseIC
Table 1Published trials using OECs for ischemic stroke.
[1]   Savitz SI, Yavagal D, Rappard G, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-stroke). Circulation 2019, 139(2): 192-205.
[2]   Sung PH, Chen KH, Lin HS, et al. The correlation between severity of neurological impairment and left ventricular function in patients after acute ischemic stroke. J Clin Med 2019, 8(2): E190.
[3]   Li JS, Zhang Q, Wang W, et al. Mesenchymal stem cell therapy for ischemic stroke: a look into treatment mechanism and therapeutic potential. J Neurol 2020: 1-13.
[4]   Kwak KA, Kwon HB, Lee JW, et al. Current perspectives regarding stem cell-based therapy for ischemic stroke. Curr Pharm Des 2018, 24(28): 3332-3340.
[5]   Boltze J, Modo MM, Mays RW, et al. Stem cells as an emerging paradigm in stroke 4: advancing and accelerating preclinical research. Stroke 2019, 50(11): 3299-3306.
[6]   Savitz SI, Chopp M, Deans R, et al. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke 2011, 42(3): 825-829.
[7]   Savitz SI, Cramer SC, Wechsler L, et al. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke 2014, 45(2): 634-639.
[8]   The STEPS Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009, 40(2): 510-515.
[9]   Jendelová P, Kubinová ?, Sandvig I, et al. Current developments in cell- and biomaterial-based approaches for stroke repair. Expert Opin Biol Ther 2016, 16(1): 43-56.
[10]   Chen LK, Qiu R, Li LS, et al. The role of exogenous neural stem cells transplantation in cerebral ischemic stroke. J Biomed Nanotechnol 2014, 10(11): 3219-3230.
[11]   Bible E, Qutachi O, Chau DY, et al. Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles. Biomaterials 2012, 33(30): 7435-7446.
[12]   Laskowitz DT, Bennett ER, Durham RJ, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase I safety study. Stem Cells Transl Med 2018, 7(7): 521-529.
[13]   Qiao LY, Huang FJ, Zhao MS, et al. A two-year follow-up study of cotransplantation with neural stem/progenitor cells and mesenchymal stromal cells in ischemic stroke patients. Cell Transplant 2014, 23(): S65-S72.
[14]   Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry 2020, 91(4): 396-401.
[15]   Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med 2011, 6(1): 45-52.
[16]   Bhasin A, Srivastava M, Bhatia R, et al. Autologous intravenous mononuclear stem cell therapy in chronic ischemic stroke. J Stem Cells Regen Med 2012, 8(3): 181-189.
[17]   Ghali AA, Yousef MK, Ragab OA, et al. Intra-arterial infusion of autologous bone marrow mononuclear stem cells in subacute ischemic stroke patients. Front Neurol 2016, 7: 228.
[18]   Bhasin A, Kumaran SS, Bhatia R, et al. Safety and feasibility of autologous mesenchymal stem cell transplantation in chronic stroke in Indian patients. A four-year follow up. J Stem Cells Regen Med 2017, 13(1): 14-19.
[19]   Jaillard A, Hommel M, Moisan A, et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl Stroke Res 2020, 11(5): 910-923.
[20]   Levy ML, Crawford JR, Dib N, et al. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke 2019, 50(10): 2835-2841.
[21]   Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg 2018: 1-11.
[22]   Augestad IL, Nyman AKG, Costa AI, et al. Effects of neural stem cell and olfactory ensheathing cell co-transplants on tissue remodelling after transient focal cerebral ischemia in the adult rat. Neurochem Res 2017, 42(6): 1599-1609.
[23]   Rao YJ, Zhu WX, Liu HJ, et al. Clinical application of olfactory ensheathing cells in the treatment of spinal cord injury. J Int Med Res 2013, 41(2): 473-481.
[24]   Huang HY, Xi HT, Chen L, et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant 2012, 21(): S23-S31.
[25]   Deumens R, van Gorp SF, Bozkurt A, et al. Motor outcome and allodynia are largely unaffected by novel olfactory ensheathing cell grafts to repair low-thoracic lesion gaps in the adult rat spinal cord. Behav Brain Res 2013, 237: 185-189.
[26]   Li L, Adnan H, Xu B, et al. Effects of transplantation of olfactory ensheathing cells in chronic spinal cord injury: a systematic review and meta-analysis. Eur Spine J 2015, 24(5): 919-930.
[27]   Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair 2010, 24(1): 10-22.
[28]   Kawabori M, Yenari MA. Inflammatory responses in brain ischemia. Curr Med Chem 2015, 22(10): 1258-1277.
[29]   Turner RJ, Vink R. The role of substance p in ischaemic brain injury. Brain Sci 2013, 3(1): 123-142.
[30]   Kawabori M, Shichinohe H, Kuroda S, et al. Clinical trials of stem cell therapy for cerebral ischemic stroke. Int J Mol Sci 2020, 21(19): 7380.
[31]   Stonesifer C, Corey S, Ghanekar S, et al. Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. Prog Neurobiol 2017, 158: 94-131.
[32]   Cui LL, Golubczyk D, Tolppanen AM, et al. Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy? Ann Neurol 2019, 86(1): 5-16.
[33]   Kuroda S, Shichinohe H, Houkin K, et al. Autologous bone marrow stromal cell transplantation for central nervous system disorders - recent progress and perspective for clinical application. J Stem Cells Regen Med 2011, 7(1): 2-13.
[34]   Misra V, Ritchie MM, Stone LL, et al. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy. Neurology 2012, 79(13 ): S207-S212.
[35]   Kawabori M, Kuroda S, Ito M, et al. Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct. Neuropathology 2013, 33(2): 140-148.
[36]   Ito M, Kuroda S, Sugiyama T, et al. Transplanted bone marrow stromal cells protect neurovascular units and ameliorate brain damage in stroke-prone spontaneously hypertensive rats. Neuropathology 2012, 32(5): 522-533.
[37]   Li MY, Zhu QB, Liu JS. Olfactory ensheathing cells in facial nerve regeneration. Braz J Otorhinolaryngol 2020, 86(5): 525-533.
[38]   Campos FSO, Pi?a-Rodrigues FM, Reis A, et al. Lipid rafts from olfactory ensheathing cells: molecular composition and possible roles. Cell Mol Neurobiol 2021, 41(3): 525-536.
[39]   Tabakow P, Jarmundowicz W, Czapiga B, et al. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplant 2013, 22(9): 1591-1612.
[40]   Tabakow P, Raisman G, Fortuna W, et al. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. Cell Transplant 2014, 23(12): 1631-1655.
[41]   Mu?oz-Quiles C, Santos-Benito FF, Llamusí MB, et al. Chronic spinal injury repair by olfactory bulb ensheathing glia and feasibility for autologous therapy. J Neuropathol Exp Neurol 2009, 68(12): 1294-1308.
[42]   Reshamwala R, Shah M, Belt L, et al. Reliable cell purification and determination of cell purity: crucial aspects of olfactory ensheathing cell transplantation for spinal cord repair. Neural Regen Res 2020, 15(11): 2016-2026.
[43]   Kim BY, Park J, Kim E, et al. Olfactory ensheathing cells mediate neuroplastic mechanisms after olfactory training in mouse model. Am J Rhinol Allergy 2020, 34(2): 217-229.
[44]   Barton MJ, John JS, Clarke M, et al. The Glia response after peripheral nerve injury: a comparison between schwann cells and olfactory ensheathing cells and their uses for neural regenerative therapies. Int J Mol Sci 2017, 18(2): E287.
[45]   Leung JY, Chapman JA, Harris JA, et al. Olfactory ensheathing cells are attracted to, and can endocytose, bacteria. Cell Mol Life Sci 2008, 65(17): 2732-2739.
[46]   Vincent AJ, Choi-Lundberg DL, Harris JA, et al. Bacteria and PAMPs activate nuclear factor kappaB and Gro production in a subset of olfactory ensheathing cells and astrocytes but not in Schwann cells. Glia 2007, 55(9): 905-916.
[47]   Dai C, Khaw PT, Yin ZQ, et al. Olfactory ensheathing cells rescue optic nerve fibers in a rat Glaucoma model. Transl Vis Sci Technol 2012, 1(2): 3.
[48]   Li J, Chen WA, Li Y, et al. Transplantation of olfactory ensheathing cells promotes partial recovery in rats with experimental autoimmune encephalomyelitis. Int J Clin Exp Pathol 2015, 8(9): 11149-11156.
[49]   Toft A, Scott DT, Barnett SC, et al. Electrophysiological evidence that olfactory cell transplants improve function after spinal cord injury. Brain 2007, 130(Pt 4): 970-984.
[50]   Sandvig I, Thuen M, Hoang L, et al. In vivo MRI of olfactory ensheathing cell grafts and regenerating axons in transplant mediated repair of the adult rat optic nerve. NMR Biomed 2012, 25(4): 620-631.
[51]   Chen JL, Zhang CL, Jiang H, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 2005, 25(2): 281-290.
[52]   López-Vales R, García-Alías G, Forés J, et al. Increased expression of cyclo-oxygenase 2 and vascular endothelial growth factor in lesioned spinal cord by transplanted olfactory ensheathing cells. J Neurotrauma 2004, 21(8): 1031-1043.
[53]   Nazareth L, Shelper TB, Chacko A, et al. Key differences between olfactory ensheathing cells and Schwann cells regarding phagocytosis of necrotic cells: implications for transplantation therapies. Sci Rep 2020, 10(1): 18936.
[54]   Toyoshima A, Yasuhara T, Date I. Mesenchymal stem cell therapy for ischemic stroke. Acta Med Okayama 2017, 71(4): 263-268.
[55]   Kawabori M, Tanimori A, Kitta S, et al. Evaluation of novel stereotactic cannula for stem cell transplantation against central nervous system disease. Stem Cells Int 2020, 2020: 4085617.
[56]   Wang LQ, Lin ZZ, Shao B, et al. Therapeutic applications of bone marrow-derived stem cells in ischemic stroke. Neurol Res 2013, 35(5): 470-478.
[57]   Mello TG, Rosado-de-Castro PH, Campos RMP, et al. Intravenous human umbilical cord-derived mesenchymal stromal cell administration in models of moderate and severe intracerebral hemorrhage. Stem Cells Dev 2020, 29(9): 586-598.
[58]   Kawabori M, Kuroda S, Sugiyama T, et al. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology 2012, 32(3): 217-226.
[59]   Chau MJ, Deveau TC, Gu XH, et al. Delayed and repeated intranasal delivery of bone marrow stromal cells increases regeneration and functional recovery after ischemic stroke in mice. BMC Neurosci 2018, 19(1): 20.
[60]   Bagheri-Mohammadi S, Alani B, Karimian M, et al. Intranasal administration of endometrial mesenchymal stem cells as a suitable approach for Parkinson's disease therapy. Mol Biol Rep 2019, 46(4): 4293-4302.
[61]   Li YH, Feng L, Zhang GX, et al. Intranasal delivery of stem cells as therapy for central nervous system disease. Exp Mol Pathol 2015, 98(2): 145-151.
[62]   Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M, et al. Stem cell therapy and administration routes after stroke. Transl Stroke Res 2016, 7(5): 378-387.
[63]   Muir KW. Clinical trial design for stem cell therapies in stroke: What have we learned? [J]. Neurochem Int 2017, 106: 108-113.
[64]   Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke: a phase 2, double-blind, randomized, controlled trial. J Neurorestoratol 2020, 8(3): 182-193.
[65]   Shyu WC, Liu DD, Lin SZ, et al. Implantation of olfactory ensheathing cells promotes neuroplasticity in murine models of stroke. J Clin Invest 2008, 118(7): 2482-2495.
[66]   Shi XZ, Kang YL, Hu Q, et al. A long-term observation of olfactory ensheathing cells transplantation to repair white matter and functional recovery in a focal ischemia model in rat. Brain Res 2010, 1317: 257-267.
[67]   Chen L, Xi HT, Huang HY, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant 2013, 22(): S83-S91.
[68]   Gopurappilly R, Pal R, Mamidi MK, et al. Stem cells in stroke repair: current success and future prospects. CNS Neurol Disord Drug Targets 2011, 10(6): 741-756.
[69]   Bliss TM, Andres RH, Steinberg GK. Optimizing the success of cell transplantation therapy for stroke. Neurobiol Dis 2010, 37(2): 275-283.
[70]   Huang HY, Chen L, Sanberg P. Cell therapy from bench to bedside translation in CNS Neurorestoratology era. Cell Med 2010, 1(1): 15-46.
[71]   Huang HY, Chen L, Sanberg PR. Clinical achievements, obstacles, falsehoods, and future directions of cell-based neurorestoratology. Cell Transplant 2012, 21(): S3-S11.
[72]   Huang HY. Neurorestoratology, a distinct discipline and a new era: a brief introduction to the first IANR section. Cell Transplant 2010, 19(2): 129-131.
[1] Yunliang Wang,Xiaoling Guo,Yanqiu Liu,Yan Li,Ying Liu,Di Chen,Juan Xiao,Wenyong Gao,Yajun Liu,Bo Zhou,Ran Liu,Fei Liu,Weidong Chen,Deqiang Guo,Gensheng Mao,Hongyun Huang. A pilot study of clinical cell therapy for patients with vascular dementia[J]. Journal of Neurorestoratology, 2021, 9(2): 137-150.
[2] Zhijian Cheng,Rui Wang,Kai Cao,Guoyu Wang,Jie Qin,Haopeng Li,Jiaxi Li,Dong Wang,Xijing He. Ten years of clinical observation of olfactory ensheathing cell transplantation in patients with spinal cord injury[J]. Journal of Neurorestoratology, 2021, 9(2): 106-116.
[3] Alok Sharma,Hemangi Sane,Amruta Paranjape,Ritu Varghese,Vivek Nair,Hema Biju,Dhanashree Sawant,Nandini Gokulchandran,Prerna Badhe. Improved survival in amyotrophic lateral sclerosis patients following autologous bone marrow mononuclear cell therapy: a long term 10-year retrospective study[J]. Journal of Neurorestoratology, 2021, 9(2): 117-136.
[4] Xiaodong Guo, Yaping Feng, Tiansheng Sun, Shiqing Feng, Jiaguang Tang, Lin Chen, Xiaojian Cao, Haodong Lin, Xijing He, Meihua Li, Zhicheng Zhang, Guoyong Yin, Xifan Mei, Hongyun Huang. Clinical guidelines for neurorestorative therapies in spinal cord injury (2021 China version)[J]. Journal of Neurorestoratology, 2021, 9(1): 31-49.
[5] Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Ying Liu, Wenyong Gao, Juan Xiao, Yanqiu Liu, Yan Li, Manli Tang, Linlin Wang, Lin Chen, Di Chen, Deqiang Guo, Fei Liu, Weidong Chen, Baomin Chan, Bo Zhou, Aibing Liu, Gengsheng Mao, Hongyun Huang. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2, double-blind, randomized, controlled trial[J]. Journal of Neurorestoratology, 2020, 8(3): 182-193.
[6] Xinyu Wang, Nan Sun, Xiangqi Meng, Meng Chen, Chuanlu Jiang, Jinquan Cai. Review of clinical nerve repair strategies for neurorestoration of central nervous system tumor damage[J]. Journal of Neurorestoratology, 2020, 8(3): 172-181.
[7] Hongyun Huang, Lin Chen, Gengsheng Mao, Hari Shanker Sharma. Clinical neurorestorative cell therapies: Developmental process, current state and future prospective[J]. Journal of Neurorestoratology, 2020, 8(2): 61-82.
[8] Changke Ma, Peng Zhang, Yixin Shen. Progress in research into spinal cord injury repair: Tissue engineering scaffolds and cell transdifferentiation[J]. Journal of Neurorestoratology, 2019, 7(4): 196-206.
[9] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[10] Ekaterina Shevela, Marina Davydova, Natalia Starostina, Alexandra Yankovskaya, Alexandr Ostanin, Elena Chernykh. Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a pilot study[J]. Journal of Neurorestoratology, 2019, 7(2): 89-100.
[11] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[12] Andrey S. Bryukhovetskiy. Translational experience of 28 years of use of the technologies of regenerative medicine to treat complex consequences of the brain and spinal cord trauma: Results, problems and conclusions[J]. Journal of Neurorestoratology, 2018, 6(1): 99-114.
[13] Hongyun Huang, Hari Shanker Sharma, Lin Chen, Ali Otom, Ziad M. Al Zoubi, Hooshang Saberi, Dafin F. Muresanu, Xijing He. Review of clinical neurorestorative strategies for spinal cord injury: Exploring history and latest progresses[J]. Journal of Neurorestoratology, 2018, 6(1): 171-178.
[14] Hongyun Huang, Lin Chen, Qingyan Zou, Fabin Han, Tiansheng Sun, Gengsheng Mao, Xijing He. Clinical cell therapy guidelines for neurorestoration (China version 2016)[J]. Journal of Neurorestoratology, 2017, 5(1): 39-46.
[15] Alok Sharma, Tongchao Geng, Hemangi Sane, Pooja Kulkarni. Clinical neurorestorative progresses in cerebral palsy[J]. Journal of Neurorestoratology, 2017, 5(1): 51-57.